Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer

BACKGROUND: Chemotherapy regimens containing a combination of anti-Her2 antibodies are effective but can be associated with cardiac toxicity. OBJECTIVES: We evaluate the outcome with a particular focus on the cardiac function of patients with Her2 over-expressed breast cancer receiving Chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zekri, Jamal, Rasool, Haleem, Rizvi, Syed Azhar J, Eldeeb, Hany, Al-Gahmi, Aboelkhair, Farag, Kamel, Rasmy, Ayman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164857/
https://www.ncbi.nlm.nih.gov/pubmed/37148305
http://dx.doi.org/10.1177/17455057231166837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164857/
https://www.ncbi.nlm.nih.gov/pubmed/37148305
http://dx.doi.org/10.1177/17455057231166837

Ejemplares similares